English PrEP Study To Use Mylan’s Generic Version Of Gilead’s Truvada

A study of tenofovir plus emtricitabine in HIV pre-exposure prophylaxis is to begin in England in September, using Mylan’s generic version of Gilead’s originator drug Truvada. Wales is running a similar trial with Truvada, while Scotland has decided to fund the drug for PrEP under the National Health Service.

HIV virus
England is to run a trial of PrEP in HIV prevention

NHS England has announced that the three-year PrEP IMPACT trial testing the efficacy of a combination of tenofovir and emtricitabine in pre-exposure HIV prophylaxis will start enrolment from early September, with full roll-out in English clinical centers expected by April 2018 at the latest.

The £10m PrEP IMPACT trial, described as “the largest single study of its type in the world,” will use Mylan’s generic version of Gilead’s originator drug Truvada, following the conclusion...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 

The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.

UK And US Regulators In Sync On RWD External Control Arms

 
• By 

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By 

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

More from R&D

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By 

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Pink Sheet Podcast: US FDA’s Big Vaccine Policy Week

Pink Sheet reporter and editors discuss the new clinical trial requirements that the FDA announced for COVID-19 vaccines, the updated label for Novavax’s newly approved COVID-19 vaccine, and other vaccine-related events that were part of a busy week for policy in the sector.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By 

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.